To assess whether the use of beta-blockers influences mortality and the incidence of major cardiovascular events in patients with diabetes and coronary heart disease (CHD).
| INTRODUCTION
The main aim of diabetes management is to prevent diabetes-related complications. Although appropriate glycaemic control reduces the risk of microvascular complications, 1 recent trials have shown that intensive glycaemic therapy may not prevent cardiovascular events. [2] [3] [4] In addition, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial reported that intensive glycaemic therapy was associated with increased risk of all-cause and cardiovascular deaths. 2 Possible explanations for higher mortality in patients with diabetes receiving intensive glycaemic therapy may be severe hypoglycaemia and weight gain, which are associated with increased risk of death and cardiovascular events. 5, 6 Current guidelines recommend the use of β-blockers in patients with coronary heart disease (CHD); [7] [8] [9] [10] however, there is no evidence supporting improved survival in patients with stable CHD without a history of myocardial infarction (MI) or heart failure with reduced left ventricular ejection fraction (HFrEF). In addition, based on the potential risk of hypoglycaemia and weight gain attributable to β-blockers, 11, 12 the disadvantages of β-blockers may outweigh the benefits in patients with diabetes and CHD. The aim of the present study, therefore, was to assess whether the use of β-blockers influences mortality and the incidence of major cardiovascular events in patients with diabetes and CHD. Recent observational studies have suggested that early β-blocker use in patients with acute MI was associated with reduced mortality, but prolonged β-blocker treatment beyond 1 year after acute MI was unlikely to improve survival. 13, 14 The results of these studies suggest a progressively decreasing benefit of β-blocker treatment over time; therefore, we also assessed whether the use of β-blockers is effective in patients with diabetes
and CHD who underwent early revascularization and had ameliorated ischaemia.
| MATERIALS AND METHODS

| Study design and patients
We used data from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial to evaluate the association between the use of β-blockers and all-cause mortality and cardiovascular events in patients with type 2 diabetes who had stable CHD. A detailed description of the BARI 2D study design, protocol and patient characteristics has been reported previously. [15] [16] [17] [18] [19] Briefly, BARI 2D was a multicentre, international, randomized, clinical trial comparing two major strategies in patients with type 2 diabetes and CHD: (1) 
| Outcome measurements
Similarly to a previous report of the main study, 15 the primary outcome in the present study was all-cause mortality. The secondary outcome was a composite endpoint including all-cause death, MI or stroke (major cardiovascular events). In addition, to analyse mortality in more detail, cardiovascular and cardiac mortality was assessed.
Cardiac death included death as a result of cardiogenic shock, MI, primary cardiac arrest or heart failure with terminal pulmonary embolism. Cardiovascular death included cardiac death and death from stroke and other atherosclerotic vascular disease. An independent Mortality and Morbidity Classification Committee adjudicated the endpoint data in the original BARI 2D study and classified the cause of all deaths and verified all strokes. More detailed information about outcome evaluation has been reported previously. 15, 20 In addition,
we evaluated the incidence of severe hypoglycaemia in patients on
and not on β-blockers. Severe hypoglycaemia was defined as hypoglycaemia requiring assistance with treatment and either a blood glucose level of <2.8 mmol/L (50 mg/dL) or confusion, irrational or uncontrollable behaviour, convulsions, or coma reversed by a treatment that raises blood glucose. 15 Patients were evaluated on a monthly basis for 6 months and every 3 months thereafter. Patients were followed until November 30, 2008, and the occurrence of outcomes was maximally followed for 6 years.
| Potential confounders
We extracted data on potential confounders at baseline, including HbA1c level was classified as <6.0%, 6.0 to 6.9% or ≥7.0%.
| Statistical analysis
The patients included in the study were first divided into two groups:
patients with a history of MI and/or HFrEF (MI/HFrEF) and those without MI/HFrEF. Each group was then further divided into those on or not on β-blockers. further adjustment in the analysis of all-cause mortality. KaplanMeier survival curves were constructed for primary and secondary outcomes in patients on and not on β-blockers.
For sensitivity analysis, we performed propensity score-matched
Cox proportional hazard analysis to assess mortality and major cardiovascular events in patients on or not on β-blockers. The propensity score was used to attempt to adjust for confounding. 21 The propensity score estimated the probability that patients would have been assigned to the use of β-blockers and was derived using a logistic regression model that included use of β-blockers as the outcome vari- 3 | RESULTS
| Characteristics of study patients
The baseline characteristics of patients with (n = 767) and without (n = 1477) MI/HFrEF are shown in Table 1 . Among patients with MI/HFrEF, those on β-blockers had a higher prevalence of hypercholesterolaemia, there were fewer with a BMI <25 kg/m 2 , and more patients took statins and aspirin than those not on β-blockers. Among patients without MI/HFrEF, those on β-blockers had a higher prevalence of hypertension and hypercholesterolaemia, a higher proportion of patients with an education level lower than high school and with mild levels of physical activity, and more use of statins and aspirin than those not on β-blockers.
| Primary and secondary outcomes
The mean (AE s. Figure 1D ]; adjusted HR 1.13, 95% CI 0.85-1.49, P = .39). To further verify these results, we performed sensitivity analysis using propensity score matching. Baseline characteristics of propensity score-matched patients with (n = 222) and without (n = 724) MI/HFrEF are shown in Table S1 . In each group with and without MI/HFrEF, there were no significant differences in their baseline characteristics between those on and not on β-blockers. All-cause mortality and the incidence of major cardiovascular events in patients with MI/HFrEF were similarly lower in those on β-blockers than in those not on β-blockers (Figure 2A and C) . In contrast, among patients without MI/HFrEF, all-cause mortality and the incidence of major cardiovascular events did not differ between those on and not on β-blockers (Figure 2B and D) .
The Kaplan-Meier survival curves and cumulative event rates for cardiovascular and cardiac deaths in patients with and without MI/HFrEF are shown in Figure 3 and Table 2 , respectively. Cardiovascular and cardiac mortality in patients with MI/HFrEF was lower in those on β-blockers than in those not on β-blockers (unadjusted HR for cardiovascular mortality: 0.58, 95% CI 0.33-1.04, P = .07
[ Figure 3A] ; unadjusted HR for cardiac mortality: 0.51, 95% CI 0.28-0.93, P = .02 [ Figure 3C ]), whereas that in patients without MI/HFrEF did not differ significantly between those on and not on β-blockers (unadjusted HR for cardiovascular mortality: 1.14, 95% CI 0.69-1.87, P = .59 [ Figure 3B ]; and unadjusted HR for cardiac mortality: 1.16, 95% CI 0.69-1.95, P = .56 [ Figure 3D] ). In addition, multivariable adjusted HRs for cardiovascular and cardiac mortality were lower in patients with MI/HFrEF on β-blockers than in those not on β-blockers (adjusted HR for cardiovascular deaths: 0.52, 95% CI 0.27-1.01, P = .05; and adjusted HR for cardiac deaths: 0.47, 95% CI 0.23-0.91, P = .02), whereas that in patients without MI/HFrEF did not differ significantly between those on and not on β-blockers (adjusted HR for cardiovascular deaths: 1.04, 95% CI 0.59-1.83, P = .89; and adjusted HR for cardiac deaths: 1.08, 95% CI 0.59-1.95, P = .79).
Unadjusted and adjusted HRs for MI and stroke were not significantly different between patients on and not on β-blockers, regardless of whether there was a history of MI/HFrEF.
The Kaplan-Meier survival curves for severe hypoglycaemia in patients with and without MI/HFrEF are shown in Figure S1 . The incidence of severe hypoglycaemia was not significantly different between patients on and not on β-blockers. Similar results were found after multivariable adjustment.
| DISCUSSION
In the present study using BARI 2D trial data, various analyses of patients with type 2 diabetes and CHD showed that the use of β-blockers in those with MI/HFrEF was associated with a decreased risk of all-cause, cardiovascular and cardiac mortality, whereas the use of β-blockers in those without MI/HFrEF was not associated with these mortalities. Among patients with MI/HFrEF, all-cause mortality in patients who received intensive medical therapy alone for CHD was significantly lower in those on β-blockers than in those not on β-blockers. This was not, however, the case in patients who had undergone coronary revascularization. In addition, the incidence of major cardiovascular events in patients without MI/HFrEF was not significantly different in those on and not on β-blockers. The In conclusion, the present study on type 2 diabetes and CHD showed that the use of β-blockers in patients with MI/HFrEF was associated with a decreased risk of all-cause mortality; however, this association was not found in patients with MI/HFrEF who underwent early coronary revascularization. In addition, among patients without MI/HFrEF, all-cause mortality did not differ between those on and not on β-blockers. To clarify the indications for β-blockers in patients with diabetes and CHD, randomized controlled trials are needed. 
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